Everything below concerns Reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-04. Numbers and descriptions here follow the published literature rather than marketing material.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
=== Pharmacokinetics and metabolism === As plecanatide acts on receptors present on the apical side of endothelial cells lining the gastrointestinal tract it is able to impart its effect without ever entering circulation. As with most orally ingested peptides, plecanatide is degraded by intestinal enzymes, and so very little of the active drug enters systemic circulation. Minimal amounts of the drug are expected to be transported in to the body, and concentrations of plecanatide and its metabolites are undetectable in plasma following the recommended dosage of 3 mg. It has also been shown that dosages up to 48.6 mg produced no detectable concentration of plecanatide in human plasma at any time point after ingestion.
== Function == Granins (chromogranins or secretogranins) are acidic proteins and are present in the secretory granules of a wide variety of endocrine and neuro-endocrine cells. The exact function(s) of these proteins is not yet settled but there is evidence that granins function as pro-hormones, giving rise to an array of peptide fragments for which autocrine, paracrine, and endocrine activities have been demonstrated in vitro and in vivo. The intracellular biochemistry of granins includes binding of Ca2+, ATP and catecholamines (epinephrine, norepinephrine) within the hormone storage vesicle core. There is also evidence that CgA, and perhaps other granins, regulate the biogenesis of dense-core secretory vesicles and hormone sequestration in neuroendocrine cells.
=== Kröhnke pyridine synthesis === In the Kröhnke pyridine synthesis, an N-pyridine-substituted methyl ketone is used as the reactant. This compound enters the keto-enol equilibrium and reacts with an enone via a Michael addition. A 1,5-dicarbonyl compound is formed, one carbonyl group of which is replaced by ammonia (or a synthesis equivalent) to form an imine. This intermediate subsequently cyclizes to give a pyridine. The reaction is named after Fritz Kröhnke, who developed it for the preparation of 2,4,6-triarylpyridines and published it in 1961.
Third and fourth generations In the 1980s, the third and fourth generations of breast prostheses featured shells coated with an elastomer that decreased gel bleed (filler leakage) into the thorax of the woman, which was achieved with thick filler-gels of various viscosities for the different models of prosthetic breast. The designs of the models of breast prostheses are anatomically symmetrical, in accordance with the body type of the woman. The shaped models realistically reproduce the types of breast hemispheres for the corresponding body-types of women. The tapered models of breast prosthesis feature a uniformly textured surface that produces friction to limit the rotation of the breast prosthesis within the implant-socket. Moreover, the round models of breast prosthesis are available in textured-surface models and in smooth-surface models, for when the prosthetic breast is not expected to rotate within the implant-socket.
Where sickle cell disease is suspected, several tests can be used. Often, a simpler, cheaper test is applied first, with a more complex test, such as DNA analysis, used to confirm a positive result. Two tests that are specific to sickle cell disease:
Sources: en.wikipedia.org
=== Homo erectus === At the beginning of the Paleolithic, hominins were found primarily in eastern Africa, east of the Great Rift Valley. Most known hominin fossils dating earlier than one million years before present are found in this area, particularly in Kenya, Tanzania, and Ethiopia. By c. 2,000,000 – c. 1,500,000 BP, groups of hominins began leaving Africa, settling southern Europe and Asia. The South Caucasus was occupied by c. 1,700,000 BP, and northern China was reached by c. 1,660,000 BP. By the end of the Lower Paleolithic, members of the hominin family were living in what is now China, western Indonesia, and, in Europe, around the Mediterranean and as far north as England, France, southern Germany, and Bulgaria. Their further northward expansion may have been limited by the lack of control of fire: studies of cave settlements in Europe indicate no regular use of fire prior to c. 400,000 – c. 300,000 BP. East Asian fossils from this period are typically placed in the genus Homo erectus. Very little fossil evidence is available at known Lower Paleolithic sites in Europe, but it is believed that hominins who inhabited these sites were likewise Homo erectus. There is no evidence of hominins in America, Australia, or almost anywhere in Oceania during this time period. Fates of these early colonists, and their relationships to modern humans, are still subject to debate. According to current archaeological and genetic models, there were at least two notable expansion events subsequent to peopling of Eurasia c. 2,000,000 – c. 1,500,000 BP.
Fast (rotary) potters' wheels enabled early mass production of pottery, but it was the use of the wheel as a transformer of energy (through water wheels, windmills, and even treadmills) that revolutionized the application of nonhuman power sources. The first two-wheeled carts were derived from travois and were first used in Mesopotamia and Iran around 3,000 BCE.
=== Surface modification improving cell adhesion === Surface modification can also affect properties that promote cell adhesion. One particular research in 2005 studied the mammalian cell adhesion on the modified surfaces of porous silicon. The research used rat PC12 cells and Human Lens Epithelial (HLE) cells cultured for four hours on the surface modified porous silicon. Cells were then stained with vital dye FDA and observed under fluorescence microscopy. The research concluded that "amino silanisation and coating the pSi surface with collagen enhanced cell attachment and spreading".
== History == The Open Insulin Project was started in 2015 by Anthony Di Franco, himself a type 1 diabetic. He started the project in response to the unreasonably high prices of insulin in the US. The project has been housed in Counter Culture Labs, a community laboratory and makerspace in the Bay Area. Other collaborators include ReaGent, BioCurious and BioFoundry.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.